<?xml version="1.0" encoding="UTF-8"?><meta xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns="http://www.w3.org/1999/xhtml" xmlns:xi="http://www.w3.org/2001/XInclude" http-equiv="Content-Type" content="text/html; charset=utf-8" />
<style xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:xi="http://www.w3.org/2001/XInclude" type="text/css">
   @media screen{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .tds_obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:95%
   }
   .test-story-main table tbody tr td{
   font-size: 110%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   font-size:100%;
   }
   .test-story-main fieldset{
   text-align:center;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   
   }
   .test-story-main table th{
   border:2px groove;
   
   }
   .test-story-main table td{
   border:1px groove;
   
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:center;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .title{
   text-align:left;
   }
   .test-story-main h3{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .pgBrk{
   padding-top:15px;
   }
   .test-story-main .er7Msg{
   width:100%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
   
   @media print{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:90%
   }
   .test-story-main table tbody tr td{
   font-size:90%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   
   }
   .test-story-main table thead tr th{
   text-align:center;
   background:#4682B4;
   
   }
   .test-story-main fieldset{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   page-break-inside:avoid;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   }
   .test-story-main table th{
   border:2px groove;
   }
   .test-story-main table td{
   border:1px groove;
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:left;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left;
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .tds_title{
   text-align:left;
   margin-bottom:1%
   }
   .test-story-main h3{
   text-align:center;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .tds_pgBrk{
   page-break-after:always;
   }
   .test-story-main #er7Message table{
   border:0px;
   width:80%
   }
   .test-story-main #er7Message td{
   background:#B8B8B8;
   font-size:65%;
   margin-top:6.0pt;
   border:0px;
   text-wrap:preserve-breaks;
   white-space:pre;
   }
   .test-story-main .er7Msg{
   width:100%;
   font-size:80%;
   }
   .test-story-main .er7MsgNote{
   width:100%;
   font-style:italic;
   font-size:80%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .embSubSpace{
   padding-left:25px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
</style>
<!-- generated by TestStory_v1.xslt Version:1.0   Profile:TestStory-->
<fieldset>
	<div class="test-story-main">
		<tabset>
			<tab heading="FULL"  vertical="false">
				<div class="panel-body">
					<div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>After being approved by FDA and CDC Finley Ira Nash (DOB 04/05/1966) is vaccinated with a new vaccine for Heartland virus (a rare tick-borne virus), along with a Hep B vaccine that the patient states is required for new employment. The patient has no record of hep B vaccine and the practitioner starts the series.<br><br><br></p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Daniela Jennifer Wyatt is the administering practitioner.</p><p><br></p><p>The vaccines have been ordered and the new VFC code IIP024 exists in the SUT.<br><br></p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) is administered a dose of Heartland Virus vaccine without a scannable 2D barcode, it has been recorded in the SUT and is visible to SUT users.</p><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) is administered a dose of Hep B adult vaccine with a scannable 2D barcode, it has been recorded in the SUT and is visible to SUT users.</p><p>Go to step 7.1.5 to transmit vaccines from this step.</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p>To test the ability that the SUT allows for manual entry of data from newly entered vaccine product in the SUT inventory.</p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) has been administered vaccines by practitioner Daniela Jennifer Wyatt and the following information is entered into the patient record and visible in the SUT:</p><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="20"><td height="20" width="371">Item 1</td><td width="185"><br></td></tr><tr height="20"><td height="20">Product Name (This may vary with each implementation)</td><td>Heartland-24_mRNA</td></tr><tr height="20"><td height="20">Date Administered</td><td>Today&#39;s date</td></tr><tr height="21"><td height="21" width="371">Unit-of-Sale (Box) NDC</td><td>8077-0743-15</td></tr><tr height="20"><td height="20">Manufacturer</td><td>Moderna</td></tr><tr height="20"><td height="20">Lot Number</td><td>HVV8071524</td></tr><tr height="20"><td height="20">Expiration Date</td><td>09/27/2029</td></tr><tr height="20"><td height="20">Unit-of-Use (Vial/Syringe)<strong>&nbsp;Image that shall not be scanned-manually entered</strong></td><td width="185">8077-0743-15</td></tr><tr height="46"><td height="46" width="371">Patient Dose-level Eligibility</td><td>IIP024 HeartlandHVV-Program</td></tr><tr height="20"><td height="20">Funding Source</td><td>Public</td></tr><tr height="20"><td height="20">Route</td><td>INTRAMUSCULAR</td></tr><tr height="20"><td height="20">Site</td><td>Left Deltoid</td></tr><tr height="32"><td height="32">VIS Given</td><td width="185">Heartland-24 Vaccine 03-28-2024 VIS</td></tr><tr height="20"><td height="20">CVX Code</td><td width="185">234</td></tr><tr height="21"><td height="21" width="371">MVX Code</td><td width="185">MOD</td></tr><tr height="38"><td height="38" width="371">Generic Name (CVX 234)</td><td width="185">HVV</td></tr><tr height="38"><td height="38" width="371">Dose/units</td><td width="185">0.5mL</td></tr></tbody></table><p><br></p><table border="0" cellpadding="0" cellspacing="0" width="526"><tbody><tr height="20"><td height="20" width="380">Item 2</td><td width="146"><br></td></tr><tr height="20"><td height="20">Product Name (This may vary with each implementation)</td><td>Hep B, adult</td></tr><tr height="20"><td height="20">Date Administered</td><td>Today&#39;s date</td></tr><tr height="21"><td height="21" width="380">Unit-of-Sale (Box) NDC</td><td>58160-0821-34</td></tr><tr height="20"><td height="20">Manufacturer</td><td>GlaxoSmithKline</td></tr><tr height="20"><td height="20">Lot Number</td><td>IIPVAXN03</td></tr><tr height="20"><td height="20">Expiration Date</td><td>9/27/2029</td></tr><tr height="20"><td height="20">Unit-of-Use (Vial/Syringe) barcode</td><td>58160-0821-05<br><br><img src="data:image/png;base64,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" alt="" class="fr-dii fr-draggable" style="width: 73px; height: 73px;"><br><br>GTIN 10358160821056</td></tr><tr height="46"><td height="46" width="380">Patient Dose-level Eligibility</td><td>Not VFC eligible</td></tr><tr height="20"><td height="20">Funding Source</td><td>Private funds</td></tr><tr height="20"><td height="20">Route</td><td>INTRAMUSCULAR</td></tr><tr height="20"><td height="20">Site</td><td>Right Deltoid</td></tr><tr height="32"><td height="32">VIS Given</td><td width="146">Hepatitis B Vaccine VIS&nbsp;</td></tr><tr height="20"><td height="20">CVX Code</td><td width="146">43</td></tr><tr height="21"><td height="21" width="380">MVX Code</td><td width="146">SKB</td></tr><tr height="38"><td height="38" width="380">Generic Name (CVX 43)</td><td>Hep B, adult</td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="526"><tbody><tr height="38"><td height="38" width="380">Dose/units</td><td width="146">0.5mL</td></tr></tbody></table></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><strong>Vaccine Eligibility /VFC (Vaccines for Children) Eligibility (financial class)</strong> refers to the criteria that determine whether an individual qualifies to receive a specific vaccine at a given time. Some patient specific factors in determining eligibility are age, insurance, income level, community risk/outbreak, and health condition.<br><br></p><p><strong>Vaccine Funding Source</strong> refers to the inventory location that the vaccine was taken from and is determined by the financial mechanism or program that covers the cost of the vaccine. If the vaccine was privately purchased and not received via any government program, then the funding source selection should be Private. If the vaccine was supplied via a government program, the funding source is Public. Some jurisdictions will have additional public funding sources such as Public non-VFC or Pandemic. Please check with the jurisdiction for funding source options. Please note: the eligibility of the patient doesn&#39;t always determine the funding source. A patient may not be eligible for a specific program but may still receive vaccine via a government program as was the case with the Covid vaccine. Example of this would be patient is Not VFC Eligible but the funding source would be Pandemic.</p></td></tr></table></div><br/>
				</div>
			</tab>
			<tab heading="Description" vertical="false"><div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>After being approved by FDA and CDC Finley Ira Nash (DOB 04/05/1966) is vaccinated with a new vaccine for Heartland virus (a rare tick-borne virus), along with a Hep B vaccine that the patient states is required for new employment. The patient has no record of hep B vaccine and the practitioner starts the series.<br><br><br></p><p><br></p></td></tr></table></div></tab><tab heading="Pre-condition" vertical="false"><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Daniela Jennifer Wyatt is the administering practitioner.</p><p><br></p><p>The vaccines have been ordered and the new VFC code IIP024 exists in the SUT.<br><br></p><p><br></p></td></tr></table></div></tab><tab heading="Post-Condition" vertical="false"><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) is administered a dose of Heartland Virus vaccine without a scannable 2D barcode, it has been recorded in the SUT and is visible to SUT users.</p><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) is administered a dose of Hep B adult vaccine with a scannable 2D barcode, it has been recorded in the SUT and is visible to SUT users.</p><p>Go to step 7.1.5 to transmit vaccines from this step.</p></td></tr></table></div></tab><tab heading="Test Objectives" vertical="false"><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p>To test the ability that the SUT allows for manual entry of data from newly entered vaccine product in the SUT inventory.</p><p><br></p></td></tr></table></div></tab><tab heading="Evaluation Criteria" vertical="false"><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>Finley Ira Nash &nbsp;(DOB 04/05/1966) has been administered vaccines by practitioner Daniela Jennifer Wyatt and the following information is entered into the patient record and visible in the SUT:</p><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="20"><td height="20" width="371">Item 1</td><td width="185"><br></td></tr><tr height="20"><td height="20">Product Name (This may vary with each implementation)</td><td>Heartland-24_mRNA</td></tr><tr height="20"><td height="20">Date Administered</td><td>Today&#39;s date</td></tr><tr height="21"><td height="21" width="371">Unit-of-Sale (Box) NDC</td><td>8077-0743-15</td></tr><tr height="20"><td height="20">Manufacturer</td><td>Moderna</td></tr><tr height="20"><td height="20">Lot Number</td><td>HVV8071524</td></tr><tr height="20"><td height="20">Expiration Date</td><td>09/27/2029</td></tr><tr height="20"><td height="20">Unit-of-Use (Vial/Syringe)<strong>&nbsp;Image that shall not be scanned-manually entered</strong></td><td width="185">8077-0743-15</td></tr><tr height="46"><td height="46" width="371">Patient Dose-level Eligibility</td><td>IIP024 HeartlandHVV-Program</td></tr><tr height="20"><td height="20">Funding Source</td><td>Public</td></tr><tr height="20"><td height="20">Route</td><td>INTRAMUSCULAR</td></tr><tr height="20"><td height="20">Site</td><td>Left Deltoid</td></tr><tr height="32"><td height="32">VIS Given</td><td width="185">Heartland-24 Vaccine 03-28-2024 VIS</td></tr><tr height="20"><td height="20">CVX Code</td><td width="185">234</td></tr><tr height="21"><td height="21" width="371">MVX Code</td><td width="185">MOD</td></tr><tr height="38"><td height="38" width="371">Generic Name (CVX 234)</td><td width="185">HVV</td></tr><tr height="38"><td height="38" width="371">Dose/units</td><td width="185">0.5mL</td></tr></tbody></table><p><br></p><table border="0" cellpadding="0" cellspacing="0" width="526"><tbody><tr height="20"><td height="20" width="380">Item 2</td><td width="146"><br></td></tr><tr height="20"><td height="20">Product Name (This may vary with each implementation)</td><td>Hep B, adult</td></tr><tr height="20"><td height="20">Date Administered</td><td>Today&#39;s date</td></tr><tr height="21"><td height="21" width="380">Unit-of-Sale (Box) NDC</td><td>58160-0821-34</td></tr><tr height="20"><td height="20">Manufacturer</td><td>GlaxoSmithKline</td></tr><tr height="20"><td height="20">Lot Number</td><td>IIPVAXN03</td></tr><tr height="20"><td height="20">Expiration Date</td><td>9/27/2029</td></tr><tr height="20"><td height="20">Unit-of-Use (Vial/Syringe) barcode</td><td>58160-0821-05<br><br><img src="data:image/png;base64,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" alt="" class="fr-dii fr-draggable" style="width: 73px; height: 73px;"><br><br>GTIN 10358160821056</td></tr><tr height="46"><td height="46" width="380">Patient Dose-level Eligibility</td><td>Not VFC eligible</td></tr><tr height="20"><td height="20">Funding Source</td><td>Private funds</td></tr><tr height="20"><td height="20">Route</td><td>INTRAMUSCULAR</td></tr><tr height="20"><td height="20">Site</td><td>Right Deltoid</td></tr><tr height="32"><td height="32">VIS Given</td><td width="146">Hepatitis B Vaccine VIS&nbsp;</td></tr><tr height="20"><td height="20">CVX Code</td><td width="146">43</td></tr><tr height="21"><td height="21" width="380">MVX Code</td><td width="146">SKB</td></tr><tr height="38"><td height="38" width="380">Generic Name (CVX 43)</td><td>Hep B, adult</td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="526"><tbody><tr height="38"><td height="38" width="380">Dose/units</td><td width="146">0.5mL</td></tr></tbody></table></td></tr></table></div></tab><tab heading="Notes" vertical="false"><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><strong>Vaccine Eligibility /VFC (Vaccines for Children) Eligibility (financial class)</strong> refers to the criteria that determine whether an individual qualifies to receive a specific vaccine at a given time. Some patient specific factors in determining eligibility are age, insurance, income level, community risk/outbreak, and health condition.<br><br></p><p><strong>Vaccine Funding Source</strong> refers to the inventory location that the vaccine was taken from and is determined by the financial mechanism or program that covers the cost of the vaccine. If the vaccine was privately purchased and not received via any government program, then the funding source selection should be Private. If the vaccine was supplied via a government program, the funding source is Public. Some jurisdictions will have additional public funding sources such as Public non-VFC or Pandemic. Please check with the jurisdiction for funding source options. Please note: the eligibility of the patient doesn&#39;t always determine the funding source. A patient may not be eligible for a specific program but may still receive vaccine via a government program as was the case with the Covid vaccine. Example of this would be patient is Not VFC Eligible but the funding source would be Pandemic.</p></td></tr></table></div></tab>
		</tabset>
	</div>
</fieldset>